Clinical Trial Update: Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating reduction of calcineurin inhibitors with conversion at 2 months to everolimus plus reduced tacrolimus in renal transplant reci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Rejection Prevention

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Everolimus (everolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: University of Toledo Health Science Campus | Conditions: Renal Transplant | Phase 4 | Status: COMPLETED | Results posted: 2022-05-26